TG Therapeutics, Inc. (TGTX)
TG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of hematologic cancers and autoimmune diseases. The company’s portfolio includes agents aimed at addressing unmet medical needs in multiple sclerosis, B-cell malignancies, and other related conditions. Based in the United States, TG Therapeutics is engaged in both research and development efforts to bring innovative treatments to patients.
Company News
TG Therapeutics reported strong Q2 2025 results with BRIUMVI sales growth, raising full-year revenue guidance to $585 million. The company is focusing on expanding product reach, developing new dosing regimens, and exploring additional indications for its multiple sclerosis therapy.
TG Therapeutics reported strong Q1 2025 financial results for its multiple sclerosis drug BRIUMVI, with $119.7 million in U.S. net sales and raised its full-year revenue guidance. The company also provided updates on its pipeline, including plans to advance subcutaneous BRIUMVI and a new therapy for progressive MS.
Several mid-cap stocks, including Bilibili, MARA Holdings, and ZEEKR Intelligent Technology, saw significant gains last week. The article highlights the top 8 mid-cap gainers and discusses the reasons behind their performance.
Upcoming U.S. retail sales and CPI reports could impact Federal Reserve interest rate cut expectations.
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?